Company intelligence / Profile preview

reVision Therapeutics, Inc.

Ridgewood, New Jersey, United Statesrevisiontx.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

reVision Therapeutics is developing REV-0100, which has received Orphan Drug Designation and Rare Pediatric Disease designation from the FDA for the treatment of Stargardt disease. The drug functions by sequestering and removing toxic lipid-bisretinoid, such as A2E. Clinical trials with Stargardt patients were expected to initiate in late 2021 or early 2022.

Therapeutic areas: Ophthalmology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

REV-0100

Unknown

Partnerships

Aequus Pharmaceuticals

Beyond the preview

Go deeper on reVision Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on reVision Therapeutics, Inc..

Explore the full profile